CONSOLIDATED STATEMENTS OF EQUITY - USD ($) $ in Thousands	Total	Cumulative Effect, Period of Adoption, Adjustment	Common Stock	Treasury	Additional Paid-In Capital	Additional Paid-In Capital Cumulative Effect, Period of Adoption, Adjustment	Accumulated Other Comprehensive Income (Loss)	Accumulated Deficit	Accumulated Deficit Cumulative Effect, Period of Adoption, Adjustment
Beginning balance, shares (in shares) at Dec. 31, 2020			670,585,576	549,907
Beginning balance at Dec. 31, 2020	$ 1,671,551		$ 6,706	$ (1,791)	$ 3,152,694		$ (4,225)	$ (1,481,833)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Equity-based compensation expense	2,647				2,647
Exercise of Common Stock options and warrants (in shares)			117,500
Exercise of common stock options and warrants	308		$ 1		307
Net income (loss)	31,078							31,078
Other comprehensive income (loss)	(9,070)						(9,070)
Ending balance, shares (in shares) at Mar. 31, 2021			670,703,076	549,907
Ending balance at Mar. 31, 2021	1,696,514		$ 6,707	$ (1,791)	3,155,648		(13,295)	(1,450,755)
Beginning balance, shares (in shares) at Dec. 31, 2020			670,585,576	549,907
Beginning balance at Dec. 31, 2020	1,671,551		$ 6,706	$ (1,791)	3,152,694		(4,225)	(1,481,833)
Ending balance, shares (in shares) at Dec. 31, 2021			690,082,283	8,655,082
Ending balance at Dec. 31, 2021	$ 1,685,126	$ (21,642)	$ 6,901	$ (1,791)	3,222,487	$ (39,100)	(30,495)	(1,511,976)	$ 17,458
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Accounting Standards Update [Extensible List]	Accounting Standards Update 2020-06
Equity-based compensation expense	$ 7,617				7,617
Exercise of Common Stock options and warrants (in shares)			55,750
Exercise of common stock options and warrants	136		$ 1		135
Net income (loss)	(55,433)							(55,433)
Other comprehensive income (loss)	(920)						(920)
Ending balance, shares (in shares) at Mar. 31, 2022			690,138,033	8,655,082
Ending balance at Mar. 31, 2022	$ 1,614,884		$ 6,902	$ (1,791)	$ 3,191,139		$ (31,415)	$ (1,549,951)